Farletuzumab-LNK4-S (DAR4)
Farletuzumab-LNK4-S (DAR4) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 4. Farletuzumab-LNK4-S (DAR4) is prepared by conjugating the anti-FRα antibody Farletuzumab (HY-P99153) with LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR4) can be used in cancer-related research.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
FR-α |
Chemical Information
-
SMILES
[Farletuzumab-LNK4-S (DAR4)]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)